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Abstract
Background: Endothelial cells (EC) grown on collagen particles inhibit intimal hyperplasia in animal models when
applied perivascularly, and this effect appears to be, at least in part, the result of EC-derived soluble factors that
suppress local vascular inflammation. To elucidate the molecular basis of the therapeutic effects of EC grown on
collagen particles, the anti-inflammatory activity of conditioned medium from these cells was characterized.
Methods: Human aortic EC (HAEC) and, for chromatin immunoprecipitation assays, human umbilical vein EC
(HUVEC) were treated with tumor necrosis factor alpha (TNFα) in the presence of conditioned medium generated
by HAEC grown on collagen particles (ECPCM), and the anti-inflammatory effects were evaluated by analysing the
expression of the inflammation-related adhesion molecules E-selectin and vascular cell adhesion molecule-1
(VCAM-1). The therapeutic activity of ECPCM was studied using the mouse strain JR5558, which develops
spontaneous choroidal neovascularisation (CNV) lesions driven by local inflammation.
Results: ECPCM significantly suppressed TNFα-induced expression of E-selectin and VCAM-1. ECPCM did not
affect the mRNA stability of the two genes, but suppressed TNFα-induced binding of the p65 subunit of NF-kB
transcription factor to E-selectin and VCAM-1 promoters. In vivo, systemic ECPCM treatment significantly reduced the
CNV area and the recruitment of activated macrophages to the lesions. Characterization of the molecule responsible
for the anti-inflammatory activity in ECPCM indicates that it is unlikely to be a protein and that it is not any of the
better characterized EC-derived anti-inflammatory molecules.
Conclusions: Medium conditioned by HAEC grown on collagen particles exhibits significant anti-inflammatory activity
via inhibition of genes that mediate inflammatory responses in EC.
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Background
As the innermost layer of blood vessels, endothelial cells
(EC) regulate vascular physiology by producing a variety
of soluble factors and metabolites that affect circulating
blood elements and the underlying vascular smooth
muscle cells (VSMC). In this way, EC control throm-
bosis, coagulation, vasomotor tone, blood flow and cell
growth [1, 2]. The endothelium also plays a key role in
immune and inflammatory reactions by regulating
leukocyte adhesion, activation and migration into the tis-
sue [1, 2]. EC are usually in a quiescent, anti-coagulant,
non-thrombogenic and non-inflammatory state [2, 3].
However, EC can be readily activated by a variety of
stimuli, including cytokines, thrombin, histamine, phys-
ical injury and active infections. Once activated, EC
express different classes of adhesion molecules that me-
diate the increased interaction with leukocytes: selectins,
such as E-selectin, which bind to carbohydrate determi-
nants on leukocytes to facilitate rolling; members of
the immunoglobulin superfamily such as intercellular
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adhesion molecule-1 (ICAM-1); and vascular cell ad-
hesion molecule-1 (VCAM-1), which binds to integ-
rins to mediate firm adhesion and trans-endothelial
migration of leukocytes [2, 4].
An uncontrolled and chronic inflammatory response
and discordant stimulation of EC are common events in
many pathological processes, including the development
of intimal hyperplasia (IH) [1, 5] and choroidal neovas-
cularisation (CNV) [6, 7]. IH is characterized by an in-
crease in the number of cells in the intima. It is a
distinctive state of vascular remodelling in which VSMC
proliferate and migrate from the medial layer into the
intima, accompanied by an increase in the amount of
extracellular matrix [8, 9], with a resultant reduction in
the vessel lumen diameter and blood flow which may re-
sult in occlusion [9, 10]. IH occurs in atherosclerotic
vessels, hypertensive pulmonary arteries, venous and
prosthetic bypass grafts and as a complication of trans-
luminal angioplasty, stent placement or surgical repair
[5, 8, 10]. CNV is characterised by inflammation and the
invasion of new and immature vessels from the chorio-
capillaris thorough the retinal pigmented epithelium at
the posterior pole of the eye, and is a major blinding
complication associated with age-related macular degen-
eration (AMD) [6, 11]. Convincing epidemiological data
suggest that AMD is associated with an increased risk
for cardiovascular disease, including IH; it is possible
that uncontrolled vascular inflammation is the common
driving factor for these pathologies [12–15].
Promising efforts to treat IH have used a cell-based
therapeutic approach in which EC were grown on a
three-dimensional (3-D) collagen matrix (EC/matrix)
that was surgically placed around or injected perivascu-
larly to angioplasty- or stent-treated vessels of porcine
or murine animal models. The animals treated with the
EC/matrix showed less restenosis and reduced inflamma-
tion compared to control untreated animals [5, 16–18].
Since the EC/matrix was delivered in the perivascular
space, at a distance from the media and intima of the
affected vessel, a soluble factor (or soluble factors) re-
leased from the cultured EC is likely responsible for the
beneficial effects.
Based on these observations, conditioned media
obtained from EC grown on 3-D collagen particles
(ECPCM) was produced and analysed for its anti-inflam-
matory potential in vitro and in vivo. In this report
we show that ECPCM reduced tumor necrosis factor
alpha (TNFα)-induced expression of pro-inflammatory
adhesion molecules in EC grown on tissue culture
plates. This anti-inflammatory effect was mediated by
inhibition of the binding by the activated NF-kB tran-
scription factor to the promoters of its target genes.
The therapeutic potential of ECPCM was also demon-
strated using an animal model of inflammation-driven
spontaneous CNV. Our findings provide insight into
the homeostatic control exerted by EC grown on 3-D
collagen particles over the vascular system and offer a
potential therapeutic strategy for the treatment of
vascular inflammation and its associated pathologies.
Methods
Cell culture
Human aortic endothelial cells (HAEC) were grown in
endothelial growth medium 2 (EGM2) and used at pas-
sages seven and eight. Human umbilical vein endothelial
cells (HUVEC) were grown in EGM2 and used at
passages six and seven. For studies of the effect of con-
ditioned medium, HAEC and HUVEC were plated in
EGM2 without hydrocortisone and treated using collec-
tion medium (phenol red free-endothelial basal medium
(EBM), 0.5 % fetal bovine serum (FBS), 50 μg/ml genta-
micin) or ECPCM. Cells and growing media were pur-
chased from Lonza (Slough, UK).
Generation of conditioned medium by EC on collagen
particles (ECPCM)
HAEC were seeded on collagen particles purified from
porcine skin (Gelfoam® powder, Pfizer, Tadworth, UK)
and cultured at 37 °C, 5 % CO2 for 15 days with media
changes every other day, in accordance with published
methods [16, 17]. On day 15 the number of viable cells
was determined in duplicated culture to ensure the de-
sirable cell density of >1.8 × 106 cells/tube was reached.
For collection of ECPCM, the growing medium was re-
placed by collection medium and the cells cultured for
an additional 24–27 h. ECPCM was collected, passed
through a sterile filter with 0.2 μm pore size (Acrodisc®
Filter, Pall Corp, Port Washington, NY), aliquoted and
stored at −80 °C.
Cytokine treatment for real-time PCR
For real-time PCR, HAEC and HUVEC were grown
on 24-well plates to ~80 % confluence, serum-starved
in collection medium for 16 h and then treated with
0.1 nM TNFα (PeproTech, Rocky Hill, NJ) in collec-
tion medium or ECPCM for 2 h at 37 °C, 5 % CO2.
For some experiments, HAEC were co-treated with
transforming growth factor (TGF)-β1 (PeproTech,
Rocky Hill, NJ) and TNFα in collection medium
for 2 h.
RNA extraction, reverse transcription and real-time PCR
RNA samples were harvested from each well using the
RNeasy Mini spin column kit (Qiagen, Hilden, Germany),
according to the manufacturer’s instructions. Reverse
transcription was performed using the QuantiTect RT
kit (Qiagen, Hilden, Germany), according to the man-
ufacturer’s instructions. Quantitative real-time PCR
Paneghetti and Ng Vascular Cell  (2016) 8:2 Page 2 of 12
was performed using specific human TaqMan probes
(Applied Biosystems, Foster City, CA) for E-selectin
(Hs00950401_m1) and VCAM-1 (Hs01003369_m1).
Human hypoxanthine-guanine phosphoribosyl trans-
ferase (HPRT1) TaqMan gene assay (4333768F) was
used as the housekeeping gene. The experiments were
performed using triplicate samples, and the data rep-
resent the average of at least three experiments ±
standard error of the mean (SEM). All data from
real-time PCR were normalized to the background
control (collection medium alone) and expressed as
fold-induction of gene expression relative to the
control.
Immunofluorescence microscopy
HAEC were grown on collagen-coated coverslips in 24-
well plates at 37 °C, 5 % CO2 until confluent. Then, EC
were serum-starved in collection medium for 16 h and
treated at 37 °C, 5 % CO2 in collection medium or
ECPCM with 0.1 nM TNFα for 10 or 30 min and 1 or
2 h. The following primary antibodies were used: rabbit
anti-p65 (Cell Signalling, Danvers, MA) and sheep anti-
PECAM-1 (R&D Systems, Abingdon, UK). AlexaFluor®
594 donkey anti-sheep and 488 donkey anti-rabbit
(Invitrogen, Paisley, UK) were used as secondary
antibodies.
Protein extraction and western blot
Confluent EC were treated with 0.1 nM TNFα and pro-
teins were extracted using radioimmunoprecipitation
assay buffer (RIPA buffer; Sigma, St. Louis, MO) with
protease and phosphatase inhibitors (Thermo Scientific,
Loughborough, UK). SDS-PAGE was performed using a
10 % polyacrylamide gel and proteins were transferred
onto a Hybond membrane. The primary antibodies
mouse anti-β actin (Sigma, St. Louis, MO), rabbit anti-
IkBα (AbCam, Cambridge, UK), rabbit anti-E-selectin,
and anti-VCAM-1 (Santa Cruz Biotechnology, CA) were
used, followed by appropriate secondary antibody
conjugated to horseradish peroxidase (GE Healthcare,
Little Chalfont, UK). Blots were developed using the
GE Healthcare (Little Chalfont, UK) ECL+ System,
according to the manufacturer’s instructions. Relative
densitometric quantification of bands in western blots
was performed using ImageJ software (https://imagej.
nih.gov/ij/).
U937 cell attachment assay
For the counting of adherent cells, HAEC were grown in
24-well plates as for immunofluorescent staining. When
confluence was reached, the cells were serum-starved in
collection medium for 16 h and then incubated in col-
lection medium or ECPCM with or without 0.1 nM
TNFα for 5 h at 37 °C, 5 % CO2. U937 cells (passage
four to seven) were stained with 2 μM calcein AM (Invi-
trogen) and added on top of the cytokine-treated EC
(300,000 cells/well) for 30 min at 37 °C, 5 % CO2. After
the incubation period EC were washed with phosphate-
buffered saline (PBS). Counting of the U937 cells at-
tached to HAEC was performed using an Olympus
BX51 microscope and a 10× objective: images of three
non-overlapping fields of each well, on triplicate cover-
slips, were taken. The number of adherent U937 cells
was determined using the automated cell counting soft-
ware Image Pro Plus (Media Cybernetics). Variation in
the number of cells was expressed as fold increase com-
pared to the untreated control (collection medium). Dif-
ferences between treatments were compared using
GraphPad Prism software and one-way ANOVA
followed by the post hoc Tukey test. The criterion for
statistical significance was p-value <0.05.
mRNA stability assay
HAEC at ~80 % confluence were serum-starved for
16 h in collection medium, pre-treated for 2 h with 0.1
nM TNFα in collection medium and then treated with
collection medium or ECPCM with 0.1 nM TNFα and
3 μg/ml of actinomycin D (Sigma, St. Louis, MO) for
an additional 30 min, 1, 2 or 4 h. Cells were processed
for gene expression analysis by real-time PCR as
described above.
Chromatin immunoprecipitation (ChIP)
HUVEC were grown on 10 cm dishes until confluent
and serum-starved in collection medium for 16 h before
being treated with 0.1 nM TNFα in collection medium
or ECPCM for 1 h at 37 °C, 5 % CO2. Cells were then
processed for chromatin fixation and extraction using
the ChIP-IT Express kit (Active Motif, La Hulpe,
Belgium) according to the manufacturer’s instructions.
Immunoprecipitation was performed using ~10 μg of
DNA in all ChIP reactions and 4 μl of anti-p65 antibody
(Active Motif, La Hulpe, Belgium) or isotype-matched
control rabbit IgG (Cell Signalling, Danvers, MA). Sam-
ples were immunoprecipitated for 16–18 h at 4 °C. The
obtained DNA was further purified using the Chromatin
IP DNA Purification kit (Active Motif, La Hulpe,
Belgium) and then used in real-time PCR. The primers
and TaqMan probes used in the PCR reaction were
designed by and purchased from Integrated DNA Tech-
nologies (Leuven, Belgium). Primers for E-selectin pro-
moter: forward 5′-TTG TCC ACA TCC AGT AAA
GAG G-3′, reverse 5′-AGG CAT GGA CAA AGG TGA
AG-3′; probe 5′-/56-FAM/CCC CAA TGG CAT CCA
AAA ACT TTC CC/36-TAMSp/-3′. Primers for
VCAM-1 promoter: forward 5′-TTA ATA GTG GAA
CTT GGCTGG G-3′, reverse 5′-GGA GTG AAA TAG
AAA GTC TGT GC-3′; probe 5′-/56-FAM/TGT TGC
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AGA GGC GGA GGG AAA T/36-TAMSp/-3′. The
immunoprecipitated DNA was quantified using a stand-
ard curve created with known concentrations of the in-
put DNA. Binding of NF-kB to the specific promoter
was calculated as fold-enrichment of the anti-p65
samples relative to the IgG control samples.
In vivo experiments
JR5558 mice on a C57BL/6J background (five genera-
tions of backcross to C57BL/6J, Jackson Laboratory, Bar
Harbor, ME) and kept as a homozygous line were used
in these studies. These mice are not yet commercially
available. The JR5558 mouse is an established model of
spontaneous CNV, and has been used successfully for
the identification and validation of a novel therapeutic
target involving inflammation-driven CNV pathogenesis
[19, 20]. Animals were kept on a 12-hour light–dark
cycle and all experiments were conducted in accordance
with Home Office guidelines (http://goo.gl/FLkirW) and
the ARVO Statement for the Use of Animals in Oph-
thalmic and Vision Research (http://goo.gl/4LFOjD).
Postnatal day (P) 21 mice were assessed for CNV lesions
through fundus fluorescein angiography (FA) using a
Kowa Genesis-Df fundus camera (Kowa, Sandhurst,
UK). The animals received daily intraperitoneal adminis-
tration of 0.5 ml of ECPCM or PBS for 7 days, from P22
to P28. Filter sterilized ECPCM or sterile buffer control
was injected into the peritoneal cavity of the mice, with-
out anesthesia, using standard 1 mL syringes equipped
with 30G needles. At the age of P29 CNV lesions were
analysed again by FA on masked samples. The area of
the lesions was calculated on FA images using Photo-
shop software. On P30, mice were euthanized and eyes
were harvested. Staining was performed using rabbit
anti-PECAM-1 and rat anti-F4/80 primary antibodies
(Abcam, Cambridge, UK). Macrophage quantification
was performed by direct cell counting on masked sam-
ples: three CNV lesions were analysed on three separate
eyes for each group, for a total of nine images for each
treatment.
Characterization of ECPCM
To calculate the IC50, confluent HAEC were serum-
starved in collection medium for 16 h before treatment.
ECPCM was serially diluted 1:2 in collection medium
and tested, together with the collection medium control,
on HAEC in the presence of 0.1 nM TNFα for 2 h at
37 °C, 5 % CO2. Cells were then processed for gene ex-
pression analysis by real-time PCR as described above.
Relative E-selectin and VCAM-1 gene induction was
expressed as percentage of control. GraphPad Prism
software was used for non-linear regression analysis of
the data for IC50 determination.
To determine if the active molecule was a protein
1 ml of ECPCM was heated at 95 °C for 15 min and ap-
proximately 0.2 units (5.5 mg) of proteinase K conju-
gated to agarose beads (Sigma, St. Louis, MO) were
added, followed by incubation at 55 °C for 16 h. The
enzyme was removed from the medium by centrifuga-
tion at 2660 × g for 10 min at 4 °C. For the RNase
A/T1 (Fermentas, Sunderland, UK) treatment 1 ml of
ECPCM was incubated with 20 μl of the enzyme mix
at 37 °C for 1 h. After each treatment the ECPCM
was cooled on ice and then stored at 4 °C until
assayed.
The Griess reagent kit for nitrite determination (Invi-
trogen Paisley, UK) was used, according to manufac-
turer’s instructions, to determine nitric oxide (NO)
levels in collection medium and ECPCM. ELISA kits for
TGF-β1, interleukin (IL)-10, cyclic AMP (cAMP) (R&D
Systems, Abingdon, UK) and prostaglandin I2 (PGI2)
(MyBioSource, Upper Heyford, UK) were used, accord-
ing to the manufacturer’s instructions, to determine the
concentration of the molecules in collection medium
and ECPCM.
Coomassie blue polyacrylamide gel staining
Forty μl of proteinase K-treated or untreated ECPCM
were mixed 1:5 with a reducing lane marker sample buf-
fer (Thermo Scientific) and boiled at 95 °C for 5 min.
Samples were loaded on a 7.5 % polyacrylamide gel for
SDS-PAGE. The gel was then fixed for 30 min in
50:10:40 methanol:acetic acid:H2O and stained another
30 min in Coomassie blue working solution [concen-
trated Coomassie blue solution (2 g brillant blue in
50 ml methanol + 6 ml acetic acid) diluted 3:58 in
5:40:10 methanol:acetic acid:H2O]. De-staining was
performed in 45:10:45 methanol:acetic acid:H2O until no
background staining was observed.
Statistics
GraphPad Prism software was used for all the statistical
analysis. Multiple groups were compared using one-way
ANOVA followed by the post hoc Tukey test, whilst
comparison between two different groups was per-
formed using the Mann-Whitney t-test. The criterion
for statistical significance was p-value <0.05.
Results
ECPCM inhibits TNFα-induced expression of E-selectin
and VCAM-1 in cultured HAEC
TNFα is a potent inflammatory cytokine that induces
expression of pro-inflammatory adhesion molecules such
as E-selectin and VCAM-1 in EC [21–26]. Because the
EC/matrix was efficacious in suppressing intimal hyper-
plasia in arteries in vivo, HAEC were deemed to be
highly relevant primary cells and were used whenever
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possible in this investigation of the anti-inflammatory
activity of ECPCM. As shown in Fig. 1a, ECPCM signifi-
cantly inhibited the TNFα-induced gene expression of E-
selectin and VCAM-1 in HAEC, by 50 and 38 %, re-
spectively, compared to control. Significant inhibition of
TNFα-induced expression of E-selectin by ECPCM was
confirmed at the protein level (Fig. 1b-c). The biological
effect of ECPCM was demonstrated through an attach-
ment assay using the U937 cells, which are myeloid cells
that adhere to the inflammation-activated endothelium.
ECPCM strongly inhibited the adhesion of U937 cells to
HAEC treated with TNFα (Fig. 1d-e).
ECPCM does not affect NF-kB pathway activation
TNFα-induced gene expression is typically mediated by
activation of nuclear factor (NF)-kB, a transcription fac-
tor composed of the p65 and p50 subunits that is known
for its important role in modulating the immune and in-
flammatory response. Activation of the pathway involves
the phosphorylation and subsequent degradation of
IkBα, the inhibitor that binds to NF-kB and retains it in
the cytoplasm [27]. Western blots were performed to
examine the protein expression levels of IkBα and im-
munofluorescence was used to determine the location of
p65 in EC treated with TNFα in collection medium or
Fig. 1 Inhibition of TNFα-induced expression of E-selectin and VCAM-1 by ECPCM. a HAEC were treated with TNFα for 2 h in collection medium
or ECPCM, then relative gene expression levels normalized to the collection media control were determined by real-time PCR analysis. Percentage
inhibition of gene expression by ECPCM was calculated by comparing treatment with ECPCM and TNFα to treatment with TNFα in collection
medium. p-value: ** <0.01 compared to TNFα in collection medium. Data =mean ± SEM. b HAEC were treated for 6 h with or without TNFα in
collection medium or ECPCM. Western blot analysis was performed with anti-VCAM-1, anti-E-selectin and anti-β-actin antibodies. The image is
representative of three separate experiments. c Relative density quantification of western blot bands for TNFα-treated HAEC in panel (b), performed
using ImageJ software. E-selectin and VCAM-1 bands were normalised to the β-actin loading control band. Data =mean ± SEM; n = 3 per treatment.
p-value: * <0.05 compared to TNFα in collection medium. d U937 cells were stained with calcein AM and then placed on top of HAEC for 30 min. After
three rinses with PBS, U937 attachment to EC was determined by counting the fluorescent cells. Changes in the number of attached cells are
expressed as fold changes over the control (treatment in collection medium). p-value: ** <0.01 compared to TNFα in collection medium. Data =Mean
± SEM. e Representative images of U937 cells stained with calcein AM and attached to cytokine-activated HAEC treated in collection medium or
ECPCM. Black background = HAEC; white dots = fluorescent U937 cells attached to the HAEC
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ECPCM. Treatment with TNFα in collection medium in-
duced IkBα degradation and NF-kB pathway activation
with p65 translocation to the nucleus in HAEC, and
ECPCM did not affect TNFα–dependent IkBα degrad-
ation or nuclear localisation of p65 (Fig. 2). These data
suggest that the anti-inflammatory activity of ECPCM is
not mediated by direct inhibition of NF-kB activation.
ECPCM decreases TNFα-induced binding of the NF-kB p65
subunit to the E-selectin and VCAM-1 promoters
Because ECPCM did not affect the activation and nuclear
translocation of NF-kB, despite inhibiting TNFα-induced
mRNA expression of E-selectin and VCAM-1, the ef-
fect of ECPCM on mRNA stability and transcriptional
control of these genes was evaluated. Treatment of
HAEC with ECPCM did not alter the mRNA stabilities
of E-selectin or VCAM-1 (Fig. 3), indicating that the in-
hibition of gene expression is not mediated by modula-
tion of mRNA stability.
To evaluate the effect of ECPCM on transcriptional
control by NF-kB, chromatin immunoprecipitation (ChIP)
experiments were performed to analyse TNFα-induced
binding of NF-kB p65 to the E-selectin and VCAM-1
promoters. HUVEC were used for this assay due to the
inability of HAEC to achieve the cell density required for
adequate isolation of nuclei. In HUVEC, as in HAEC,
ECPCM suppresses TNFα-induced expression of E-selectin
and VCAM-1 without suppressing NF-kB activation
and nuclear translocation (Additional file 1: Figure S1).
ECPCM significantly suppressed TNFα-induced binding
of p65 to the promoters of both E-selectin and VCAM-1
in HUVEC, to levels similar to those observed for the
TNFα-free control (Fig. 4). These data suggest that
ECPCM exerts its anti-inflammatory activity on TNFα
mainly by inhibiting binding of NF-kB p65 to the pro-
moters of target genes such as E-selectin and VCAM-1,
thereby suppressing transcription of pro-inflammatory
genes.
ECPCM shows anti-inflammatory activity in an animal
model of spontaneous CNV
To determine the therapeutic potential of ECPCM in
vivo, a mouse model of inflammatory CNV was used.
The JR5558 mouse is an established genetic model of
spontaneous, multi-focal, bilateral CNV discovered as a
spontaneous mutant line at the Jackson Laboratory [20].
Fig. 2 ECPCM does not affect TNFα-dependent activation of NF-kB or nuclear translocation of p65 in HAEC. a HAEC were treated for 30 min with
collection medium or with TNFα in collection medium or ECPCM. Western blot analysis was performed using antibodies for β-actin and IkBα.
TNFα induced IkBα degradation, and therefore NF-kB pathway activation, when collection medium or ECPCM was used during the treatment. The
experiment was repeated at least three times with similar results, and representative blots are shown. Bottom panel, relative densitometric quantification of
western blot bands for TNFα-treated HAEC. IκBα bands were normalised to the β-actin loading control band. Data =mean ± SEM; n= 5 per treatment.
p-value: * <0.05 compared to collection medium control. b HAEC were treated with or without TNFα in collection medium or ECPCM for 10 min, 30 min,
1 h or 2 h. Immunofluorescence staining was performed with anti-PECAM-1 (red) and anti-p65 (green) antibodies. TNFα induced nuclear translocation of
p65 upon treatment in both collection medium and ECPCM. Control: cells incubated in collection medium or ECPCM without TNFα for 2 h. Some nuclei
are outlined with white dots to highlight the translocation of p65
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These mice harbour a homozygous recessive mutation
in an unknown gene(s) that leads to formation of subret-
inal neovascular tufts that originate from the chorioca-
pillaris, starting between post-natal day P10 and P15.
The CNV lesions are accompanied by macrophage infil-
tration and systemic depletion of monocytes and macro-
phages decreases lesion size without affecting lesion
number, confirming that local inflammation and ma-
crophage activity play a significant role in driving the
growth of the CNV [6, 19, 20]. Fundus fluorescein
angiography (FA) analysis was performed on JR5558
mice at P21 (day 0) to measure the baseline area of each
CNV lesion. Animals were then treated for 7 days with
intraperitoneal injection of ECPCM or buffer control.
Lesion measurements by FA were repeated at P29
(day 8), and eyes were collected for immunostaining
analysis at P30 (day 9).
Figure 5a-b shows that treatment with ECPCM for
7 days significantly reduced the area of CNV lesions per
retina compared to the control treatment. Indeed, from
day 0 (P21) to day 8 (P29) the average CNV area per
retina increased by ~6 % in control mice, whereas it
decreased by ~30 % on average in animals treated with
ECPCM. No reduction in lesion number per retina was
detected in any group (data not shown). Furthermore,
macrophage recruitment to the CNV was reduced in
animals treated with ECPCM compared to buffer
control-treated mice (Fig. 5c-d). These results indicate
the presence of at least one potent, soluble anti-
inflammatory factor in the ECPCM.
Characterisation of the anti-inflammatory activity
To determine the IC50 of the anti-inflammatory activity,
HAEC were treated with TNFα in serially diluted sam-
ples of ECPCM and levels of E-selectin and VCAM-1
mRNA were used as endpoints. ECPCM inhibited
TNFα-induced expression of E-selectin and VCAM-1 in
a dose-dependent manner, with an IC50 of 57 % ECPCM
for E-selectin and 46 % ECPCM for VCAM-1 (Fig. 6a).
A different lot of ECPCM was also tested in a separate
experiment and produced similar results (data not
shown). These data suggest that the anti-inflammatory
activity in ECPCM is mediated by a soluble factor(s) that
can be concentrated for further study.
It was next determined if the anti-inflammatory sol-
uble factor in ECPCM might be a proteinase K-sensitive
protein. ECPCM samples were incubated with protein-
ase K, a broad-spectrum serine protease, then separated
on a polyacrylamide gel. Coomassie blue staining re-
vealed substantial digestion of proteins in the sample
(Additional file 2: Figure S2). The proteinase K-treated
ECPCM significantly suppressed TNFα-induced expres-
sion of E-selectin and VCAM-1 in HAEC, with activity
similar to that of the non-proteinase K-treated ECPCM
(Fig. 6b). The anti-inflammatory factor in ECPCM is
therefore not sensitive to proteinase K digestion and
might not be a protein.
In recent years, it has been demonstrated that RNA
molecules play important regulatory roles in cells. To
determine if RNA molecules contribute to the anti-
inflammatory effect, ECPCM was treated with a mix of
RNase A/T1 exoribonucleases that degrade single strand
RNA (ssRNA). In HAEC the RNase-treated ECPCM
inhibited TNFα-stimulated expression of E-selectin and
Fig. 3 ECPCM treatment does not affect mRNA stability of E-selectin
or VCAM-1 transcripts. HAEC were treated with TNFα in collection
medium for 2 h. The medium was then changed to collection
medium + TNFα (dotted line), collection medium + TNFα + actinomycin
D (black line) or ECPCM + TNFα + actinomycin D (grey line). Transcript
levels were assessed by real-time PCR after 30 min, 1, 2 and 4 h of
treatment. The mRNA stability for both genes did not change upon
ECPCM treatment. Data =mean ± SEM
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VCAM-1 to levels comparable to those observed with
untreated ECPCM (Fig. 6b).
EC produce and release many molecules that control
vascular physiology and homeostasis. Those with anti-
inflammatory effects include NO [1–3], PGI2 [1–3, 28–30],
TGF-β1 [31–34], IL-10 [35–40], and cAMP [41, 42]. To
determine if any of these molecules were mediating the
anti-inflammatory activity of ECPCM, their concentrations
in the conditioned medium were compared to the levels
detected in collection medium (Table 1). Levels of
TGF-β1 were far greater in ECPCM than in the collec-
tion medium control. However, TGF-β1 is not resistant
to proteinase K degradation, and collection medium
supplemented with acid-activated TGF-β1 to a level
higher to that observed in ECPCM (1000 pg/ml) failed
to inhibit TNFα-induced expression of E-selectin and
VCAM-1 (Additional file 3: Figure S3). Together these
data suggest that TGF-β1 is not responsible for ECPCM
anti-inflammatory activity. The levels of IL-10 and NO
were lower in ECPCM than in collection medium, and
levels of cAMP and PGI2 were similar between the
samples tested. Based on these data, IL-10, cAMP, PGI2
and NO were also excluded as possible mediators of
ECPCM anti-inflammatory activity.
Overall, the results suggest that the soluble anti-
inflammatory factor in ECPCM is not ssRNA; if it is a
protein, it is proteinase K-resistant; and it is not any
of the well-characterized anti-inflammatory molecules
tested in our study.
Discussion
EC are important producers of molecules that regulate
vascular homeostasis. Although the nature and function
of many EC-derived molecules have been identified over
the past three decades, the EC secretome has by no
means been completely defined. Here we offer some
insight into a soluble anti-inflammatory factor released
by EC in 3D culture in vitro and we demonstrate that
systemic administration of this factor can reduce
inflammation-associated CNV in vivo.
The NF-kB family of transcription factors plays an im-
portant role in mediating TNFα-induced expression of
pro-inflammatory genes in EC [27, 43]. Soluble TNFα
receptors are known to suppress pro-inflammatory ac-
tivity, but it is unlikely that this is the mechanism
employed by ECPCM, since ECPCM does not prevent
TNFα-induced activation of NF-κB p65, nuclear trans-
location of p65, or turnover and degradation of IkBα in
HAEC or HUVEC. Moreover, ECPCM does not affect
the mRNA stability of E-selectin and VCAM-1. An ex-
planation of the mechanism of action for ECPCM was
provided by the ChIP experiments, which showed that
ECPCM significantly reduces p65 binding to E-selectin
and VCAM-1 promoters, thus inhibiting the transcrip-
tion of these adhesion molecules upon TNFα stimula-
tion in HUVEC. Binding of p65 to DNA is controlled by
ubiquitination or acetylation of four lysine residues (Lys-
122, −123, −314 and −315) [43]. Ubiquitination of p65
promotes its release from chromatin by targeting the
protein for proteasomal degradation [43]. Since im-
munofluorescence analysis showed no detectable red-
uction in p65 levels upon ECPCM treatment, the
degradation mechanism is unlikely to be involved.
Acetylation of Lys-122 and −123 residues reduces p65
binding to DNA [44], and acetylated p65 is more easily
exported to the cytoplasm [44]. Since immunostaining at
different time points revealed no detectable difference in
the nuclear translocation of p65 between ECPCM- and
collection medium-treated EC, this mechanism can
likely be excluded. Alternative mechanisms not excluded
by our analysis include blocked acetylation at Lys-221
[45, 46], alkylation on Cys-38 [47, 48], reduced inter-
action between p65 and one or more of its many co-
factors, or effects on the target DNA that prevent the
Fig. 4 ECPCM significantly decreases binding of p65 to E-selectin and VCAM-1 promoters upon TNFα treatment. HUVEC were treated for 1 h with
or without TNFα in collection medium or ECPCM. The extracted chromatin was immunoprecipitated using anti-p65 antibody or isotype-matched
IgG as control. The immunoprecipitated DNA was then quantified using real-time PCR. The level of p65 binding to the specific promoters was
expressed as fold-change over the IgG control. p-value: * <0.01, ** <0.001 comparing ECPCM + TNFα to collection medium + TNFα
treatment. Data =mean ± SEM
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binding of transcription factors to their target sequence
on the promoter [49, 50].
The molecule responsible for ECPCM anti-inflammatory
activity is resistant to proteinase K digestion and is not
ssRNA-based. The anti-inflammatory activity might be
mediated by a novel proteinase K-resistant protein or by
double-stranded RNA. Double-stranded RNA in the
form of microRNA (miRNA) alters expression of
genes and proteins, primarily by negatively regulating
post-transcriptional events via mRNA degradation
and/or inhibition of translation [50]. Indeed, miRNA-
10a regulates the pro-inflammatory phenotype of the
endothelium through a post-transcriptional mechan-
ism [51]. There is currently no mechanism to directly
remove double-stranded RNA in solution, but since
mRNA degradation of E-selectin and VCAM-1 was
not affected by ECPCM, miRNA seems an unlikely
candidate for mediating the anti-inflammatory activity.
Other methods used to characterize the anti-
inflammatory factor(s) in ECPCM included heparin-
agarose affinity purification, size-fractionation by column
chromatography and dialysis cassettes. These techniques
failed to generate useful information about the nature
of the anti-inflammatory factor(s) because the anti-
inflammatory activity of ECPCM was lost after each
of these treatments (data not shown). It is unlikely
that Gelfoam® alone mediated this anti-inflammatory
activity, since the filtration process removed most if
not all of the Gelfoam® used in the 3-D culture, but
we cannot completely rule out a potential role for a
Fig. 5 ECPCM reduces CNV area and macrophage recruitment to CNV lesions. JR5558 mice received daily intraperitoneal injections of ECPCM or
PBS from P22 (day 1) to P28 (day 7). a Representative early phase fluorescein angiography images obtained from JR5558 mice before (P21, day 0)
and after (P29, day 8) 7 days of treatment with either PBS or ECPCM. b CNV area/retina was determined at baseline (day 0) and after the treatment
(day 8) using fluorescein angiography. The graph shows the % increase or decrease in CNV area/retina at day 8 compared to day 0 (+5.9 % for PBS
and −29.89 % for ECPCM treatment). p-value: * <0.05. Data =mean ± SEM. c After 7 days of treatment with ECPCM or PBS, eyecups were collected and
stained with anti-F4/80 antibody for activated macrophages (green) and anti-PECAM-1 antibody for EC (red) of the CNV. Two representative images for
each group of treatment are shown. d Quantification of macrophage recruitment at CNV lesions expressed as macrophage number around each
lesion. p-value: * <0.05. Data =mean ± SEM
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soluble component released from the Gelfoam®. Work
is on-going to identify the specific factor (or factors)
that mediate the anti-inflammatory effects of ECPCM.
It is possible that the activity that we have identified
in ECPCM maintains the EC in a non-inflammatory
state under normal physiological conditions, promoting
homeostasis and preventing excessive or uncontrolled
EC activation. The anti-thrombotic state of the normal
endothelium, for example, is maintained by a variety of
molecules, both secreted and localized to the cell sur-
face [1–3]. The anti-inflammatory activity we identified
can act at distal sites and potentially contribute to
systemic anti-inflammatory homeostasis of the vascula-
ture. Interestingly, conditioned medium obtained from
a similar EC/matrix culture was recently reported to
have potent inhibitory effects on activation of dendritic
cells and pro-inflammatory signalling associated with
cancer progression [52, 53]. Collagen matrix culture
may promote anti-inflammatory activity in other
epithelia as well. Bronchial epithelial cells cultured in a
similar 3-D collagen matrix produced bioactive com-
pounds that facilitated airway repair, at least in part by
reducing tissue inflammation [54].
We have demonstrated the anti-inflammatory effects
of ECPCM in an animal model of spontaneous CNV
associated with and driven by inflammation [19, 20].
CNV is a major blinding complication associated with
Fig. 6 a Dose-dependent anti-inflammatory effects of ECPCM. HAEC were treated for 2 h with TNFα in collection medium, ECPCM, or serial dilutions
(1:2) of ECPCM in collection medium. The graph shows the percentage of expression of E-selectin and VCAM-1 relative to that observed for TNFα in
collection medium, as determined by real-time PCR analysis. Data =mean ± SEM. b ECPCM anti-inflammatory activity is not affected by proteinase K or
RNase treatment. Gene expression of E-selectin and VCAM-1 was analysed by real-time PCR after treatment for 2 h with TNFα. HAEC were treated with
collection medium, ECPCM or ECPCM previously treated with proteinase K or RNase. p value: * <0.001 compared to treatment with TNFα in collection
medium. Data =mean ± SEM
Table 1 Average concentration of known anti-inflammatory
molecules in collection medium and ECPCM
Collection
medium
ECPCM Analysis concentration range
Min Max
TGF-β1 (pg/ml) 61.81 749.4 0 2000
IL-10 (pg/ml) 77.62 44.96 0 500
cAMP (pmol/ml) 6.5 6.5 3.25 240
NO (μM) 21.72 0.072 0 50
PGI2 (ng/ml) <2.5 <2.5 0 50
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AMD and is characterised by pathological inflammation
and angiogenesis [6, 11]. The reduction in macrophage
recruitment and associated CNV lesion size following
treatment with ECPCM is particularly promising given
that intraperitoneal delivery reduced local inflammatory
reactions in the eye and also that only a small volume of
unconcentrated ECPCM was sufficient for this response.
The anti-CNV effect of ECPCM is consistent with the
pre-clinical observation that EC/matrix formulation
surgically placed perivascularly significantly reduced IH
as well as leukocyte recruitment to the injured vessels
in animal models [16]. The EC/matrix formulation
(Vascugel®) is currently in phase II clinical trials for
treating IH associated with arteriovenous access and
graft failure in patients with end-stage renal disease
(http://www.shiretrials.com/studies/). Our data confirm
the potent anti-inflammatory effect of this therapy and
support further characterization and identification of this
novel activity in ECPCM, as well as its translational
research for treating vascular inflammation associated
with various pathologies. Our findings also provide new
insights into EC biology and confirm the prominent role
of EC-derived factors in regulating vascular homeostasis.
Conclusions
Our study showed that conditioned medium from EC
grown on collagen particles has a potent anti-inflammatory
activity, both in vitro and in vivo, which is mediated by the
inhibition of the binding by the activated transcription
factors to the promoters of pro-inflammatory genes. These
results provide a novel potential therapeutic strategy for the
treatment of vascular inflammation and its associated
pathologies.
Additional files
Additional file 1: Figure S1. In HUVEC, as in HAEC, ECPCM inhibits
TNFα-induced expression of E-selectin and VCAM-1 without affecting TNFα-
dependent activation of NF-kB and nuclear translocation of p65. (A) HUVEC
were treated with TNFα for 2 h in collection medium or ECPCM, then
relative gene expression levels were determined by real-time PCR analysis
and normalized to the collection medium control. Percentage inhibition of
gene expression by ECPCM was calculated by comparing treatment with
ECPCM plus TNFα to treatment with TNFα in collection medium. p-value:
*** <0.001 compared to TNFα in collection medium. Data =mean ± SEM.
(B) HUVEC were treated with or without TNFα in collection medium or
ECPCM for 10 min, 30 min, 1 h or 2 h. Immunofluorescence staining was
performed using anti-PECAM-1 (red) and anti-p65 (green) antibodies. TNFα
induced nuclear translocation of p65 in both collection medium and
ECPCM. Control: cells incubated in collection medium or ECPCM without
TNFα for 2 h. Some nuclei of the cells are outlined with white dots
to highlight the translocation of p65. Interestingly, activation of NF-kB
p65 by TNFα occurred more rapidly and lasted longer in HUVEC compared
to HAEC (C) HUVEC were treated for 30 min with collection medium or with
TNFα in collection medium or ECPCM. Western blot analysis was performed
using antibodies to β-actin and IkBα. The experiment was repeated at least
three times with similar results. Representative blots are shown. Right panel,
relative densitometric quantification of western blot bands for TNFα-treated
HUVEC, performed using ImageJ software. IκBα bands were normalised to
the β-actin loading control band. Data =mean ± SEM; n = 4 per treatment.
p-value: *** <0.001 compared to collection medium control. (PDF 1529 kb)
Additional file 2: Figure S2. Coomassie blue staining of untreated- and
proteinase K-treated ECPCM. The band of ~65 kDa in the ECPCM lane
corresponds to serum albumin. Absence of this band in the proteinase
K-treated ECPCM lane confirmed substantial protein digestion. This
experiment was repeated three times with similar results; representative
images are shown. (PDF 51 kb)
Additional file 3: Figure S3. TGF-β1 effects on cytokine-induced
expression of E-selectin and VCAM-1. HAEC were treated for 2 h with 0.1
nM TNFα in ECPCM, collection medium or collection medium with
increasing amounts of TGF-β1. Relative gene expression levels were
determined by real-time PCR analysis and normalized to the collection
medium control. p-value: * <0.05 compared to treatment in collection
medium with TNFα. Data = mean ± SEM. (PDF 230 kb)
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